Backed by Goldman Sachs, Novo Nordisk’s parent company and others, Newleos Therapeutics debuted Thursday with $94 million and a plan to develop drugs for brain function and health.

Helmed by Roche alums, Newleos Therapeutics is taking over four drugs dropped from the Swiss pharma’s pipeline in early 2024.

UBS upgraded Roche (RHHBY) to Buy from Neutral with a price target of CHF 338, up from CHF 300. The company offers sustainable growth with ...

UBS analyst Matthew Weston upgraded Roche Holding (OTC:RHHBY) stock from Neutral to Buy, adjusting the price target to CHF 338.00, up from the previous CHF 300.00. The upgrade comes as the stock ...

Newleos Therapeutics emerged Thursday with $93.5 million and a bundle of oral small molecules that it licensed from Roche, ...

Newleos Therapeutics is making its debut with $93.5 million aimed at developing safer and more effective neuroscience treatments with several clinical programs from Swiss major Roche in hand. | ...

Royalty Pharma's Q4 results show portfolio receipts of $742 million and operating cash flow of $678 million. Read why RPRX ...

Over the past nine years, patients with spinal muscular atrophy have seen the number of FDA-approved treatment options for ...

Roche (RHHBY) announced that the Food and Drug Administration has approved a New Drug Application for an Evrysdi tablet for people living with ...

The "Pharmaceutical Review Designations: Trends and Industry Insights" report has been added to ResearchAndMarkets.com's offering.This report investigates review designations in the pharmaceutical ...

Regeneron Pharmaceuticals beat fourth-quarter sales and profit estimates on Tuesday, on continuing demand for its eczema ...

A global pharmaceutical company partnered with DelveInsight to create a robust and simplified solution enabling its top executives to monitor the evolving breast cancer competitive intelligence ...